Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 23:13:862369.
doi: 10.3389/fneur.2022.862369. eCollection 2022.

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

Charles G Withington  1 , R Scott Turner  1
Affiliations
Review

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

Charles G Withington et al. Front Neurol. .

Abstract

Second-generation anti-amyloid monoclonal antibodies are emerging as a viable therapeutic option for individuals with prodromal and mild dementia due to Alzheimer's disease (AD). Passive immunotherapy with aducanumab (Aduhelm), lecanemab, donanemab, and gantenerumab all lower CNS amyloid (Aβ) burden but come with a significant risk of amyloid-related imaging abnormality (ARIA)-the most common side effect of this class of drugs. While usually asymptomatic and detected only on brain MRI, ARIA may lead to new signs and symptoms including headache, worsening confusion, dizziness, visual disturbances, nausea, and seizures. In addition, one fatality related to ARIA-E (edema) with aducanumab and one fatality due to ARIA-H (hemorrhage) with donanemab are reported to date. ARIA-E may be associated with excessive neuroinflammation and saturation of perivascular clearance pathways, while ARIA-H may be related to vascular amyloid clearance with weakening and rupture of small blood vessels. The risk of ARIA-E is higher at treatment initiation, in ApoE4 carriers, with higher dosage, and with >4 of microhemorrhages on a baseline MRI. The risk of ARIA-H increases with age and cerebrovascular disease. Dose titration mitigates the risk of ARIA, and contraindications include individuals with >4 microhemorrhages and those prescribed anti-platelet or anti-coagulant drugs. A brain MRI is required before aducanumab is initiated, before each scheduled dose escalation, and with any new neurologic sign or symptom. Management of ARIA ranges from continued antibody treatment with monthly MRI monitoring for asymptomatic individuals to temporary or permanent suspension for symptomatic individuals or those with moderate to severe ARIA on MRI. Controlled studies regarding prevention and treatment of ARIA are lacking, but anecdotal evidence suggests that a pulse of intravenous corticosteroids may be of benefit, as well as a course of anticonvulsant for seizures.

Keywords: ARIA-E; ARIA-H; Alzheimer's disease; aducanumab; amyloid related imaging abnormalities.

PubMed Disclaimer

Conflict of interest statement

RT is a site PI for studies of all of the monoclonal antibodies under discussion, with research funding from Biogen, Eisai, Lilly, and Roche/Genentech to Georgetown University. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Chiong W, Tochin BD, Bonnie RJ, Busl K, Cruz-Flores S, Epstein LG, et al. . Decisions with patients and families regarding aducanumab in Alzheimer disease, with recommendations for consent: AAN position statement. Neurology. (2022) 98:154–9. 10.1212/WNL.0000000000013053 - DOI - PubMed
    1. Aduhelm [package insert] . Cambridge, MA: Biogen; (2021).
    1. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. . A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alz Res Therapy. (2021) 13:80. 10.1186/s13195-021-00813-8 - DOI - PMC - PubMed
    1. Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, et al. . Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. Alz Res Therapy. (2016) 8:14. 10.1186/s13195-016-0181-2 - DOI - PMC - PubMed
    1. Mintun MA, Lo AC, Evans CD, Wessels AM, Ardayfio PA, Andersen SW, et al. . Donanemab in early Alzheimer's disease. N Engl J Med. (2021) 384:1691–704. 10.1056/NEJMoa2100708 - DOI - PubMed

LinkOut - more resources